Boonshoft School of Medicine

Mindera Health™ Announces Contract With General Services Administration®

Retrieved on: 
Tuesday, October 10, 2023

San Diego, CA, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Mindera Health today announced that the General Services Administration (GSA) has granted a 5 year contract award to Mindera Health enabling access to their proprietary technology, Mind.Px.

Key Points: 
  • San Diego, CA, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Mindera Health today announced that the General Services Administration (GSA) has granted a 5 year contract award to Mindera Health enabling access to their proprietary technology, Mind.Px.
  • The Mind.Px test is the first and only test that provides a personalized approach selecting the class of biologic therapy a patient with plaque psoriasis is most likely to respond to.
  • The decision is effective today and enables access to Mind.Px for those eligible for treatment at government-affiliated facilities including the over 9.6 million veterans, active duty, retirees and their families that are served by the Veteran’s Administration Health System and Department of Defense Medical Treatment Facilities, and others.
  • “Mind.Px addresses an unmet need in the effective management of plaque psoriasis patients by informing the selection of the most efficacious class of biologic therapy for a particular patient.” said Dr. Jeffrey Travers, Professor and Chair of Pharmacology and Toxicology and Professor of Dermatology at the Boonshoft School of Medicine at Wright State University and VA investigator at the Dayton VA Medical Center with no formal ties to Mindera Health.

Myrtelle Announces Presentation of Positive 6-month Post-Treatment Data in Its First-in-Human Clinical Study of rAAV-Olig001-ASPA Gene Therapy in Canavan Disease at the American Society of Gene and Cell Therapy 26th Annual Meeting

Retrieved on: 
Tuesday, May 16, 2023

Clinical measurements of motor and cognitive function using validated assessment scales demonstrate mean absolute and percent improvements across multiple domains.

Key Points: 
  • Clinical measurements of motor and cognitive function using validated assessment scales demonstrate mean absolute and percent improvements across multiple domains.
  • Improvements in multiple anatomic and biomarker measurements by magnetic resonance imaging (MRI) and spectroscopy (MRS) have also been observed.
  • These improvements in treated patients contrast the deterioration in untreated age-matched CD patients in Myrtelle’s natural history data set.
  • In CD, normal brain development is impaired due to a mutation in the ASPA gene that encodes the enzyme aspartoacylase.

Myrtelle to Host Symposium on Gene Therapies Targeting Oligodendrocytes and Implications in Brain Function and Disease States at the American Society of Gene and Cell Therapy 26th Annual Meeting in Los Angeles on Friday, May 19, 2023

Retrieved on: 
Wednesday, May 10, 2023

The symposium will highlight historical and emerging views of oligodendrocytes in normal brain function and a growing array of disease states, including leukodystrophies and disorders of myelin production such as multiple sclerosis.

Key Points: 
  • The symposium will highlight historical and emerging views of oligodendrocytes in normal brain function and a growing array of disease states, including leukodystrophies and disorders of myelin production such as multiple sclerosis.
  • Oligodendrocytes perform numerous key functions in the brain - including the production of myelin, the insulating material that enables proper neuronal function – and are now appreciated as having roles in a range of diseases.
  • Myrtelle is developing a unique toolkit, including a proprietary class of recombinant adeno-associated virus (rAAV) vectors that directly target these cells.
  • “Given the intractable nature of many neurological diseases, these cells represent important brain components worthy of interrogation in the quest for novel interventions, including gene therapies.

Myrtelle Announces Positive 6-month Post-Treatment Data in Patients in Its First-in-Human Clinical Study of rAAV-Olig001-ASPA Gene Therapy in Canavan Disease

Retrieved on: 
Wednesday, April 19, 2023

In several domains, the observed improvement in treated patients are in contrast to the observed deterioration in untreated age-matched CD patients within Myrtelle’s natural history data set.

Key Points: 
  • In several domains, the observed improvement in treated patients are in contrast to the observed deterioration in untreated age-matched CD patients within Myrtelle’s natural history data set.
  • In CD, normal brain development is impaired due to a mutation in the ASPA gene that encodes the enzyme Aspartoacylase (ASPA).
  • The oligodendrocyte-targeting rAAV vector-based gene therapy is intended to restore ASPA function and hence the metabolism of NAA and brain development in patients with CD.
  • In addition, volumetric MRI (magnetic resonance imaging) measurements showed increases in multiple brain tissue compartments and reductions in CSF volume.

Myrtelle Announces Positive Interim Data in Phase 1/2 Clinical Trial of Its Proprietary Investigational Gene Therapy rAAV-Olig001-ASPA in Canavan Disease

Retrieved on: 
Monday, January 9, 2023

Early data from the study, being conducted at Dayton Children’s Hospital (Dayton, Ohio), at three months following gene therapy treatment have shown encouraging results to date.

Key Points: 
  • Early data from the study, being conducted at Dayton Children’s Hospital (Dayton, Ohio), at three months following gene therapy treatment have shown encouraging results to date.
  • The observed improvements following gene therapy are in contrast to the continuous clinical decline expected for untreated CD patients.
  • The first three patients treated with the gene therapy in cohort one are now at least 18 months post therapy.
  • “The early results to date in patients treated in Myrtelle’s Phase 1/2 clinical trial are encouraging.

Experity Appoints Dr. Benjamin Barlow as Chief Medical Officer 

Retrieved on: 
Tuesday, November 29, 2022

Experity , the national leader in on-demand healthcare solutions, has appointed Dr. Benjamin Barlow as Chief Medical Officer.

Key Points: 
  • Experity , the national leader in on-demand healthcare solutions, has appointed Dr. Benjamin Barlow as Chief Medical Officer.
  • View the full release here: https://www.businesswire.com/news/home/20221129005400/en/
    Dr. Benjamin Barlow, Chief Medical Officer of Experity (Photo: Business Wire)
    Dr. Barlow brings nearly two decades worth of invaluable experience in the medical field, and we are privileged to have him share his expertise with Experity as our Chief Medical Officer, said Dr. David Stern, CEO, Experity.
  • Dr. Barlow joins Experity after serving as the CMO at American Family Care, the nations largest urgent care provider.
  • As the largest EMR vendor in urgent care, Experity is uniquely positioned to transform the industry of on-demand care, said Dr. Barlow.

Myrtelle Announces Positive Data for Its investigational Proprietary rAAV-Olig001-ASPA Gene Therapy in Canavan Disease at the National Tay Sachs & Allied Diseases Association Conference

Retrieved on: 
Friday, July 8, 2022

In CD, the production of myelin is affected due to a mutation in the Aspartoacylase gene (ASPA) encoding the enzyme Aspartoacylase (ASPA).

Key Points: 
  • In CD, the production of myelin is affected due to a mutation in the Aspartoacylase gene (ASPA) encoding the enzyme Aspartoacylase (ASPA).
  • These improvements suggest the gene therapy and the route of administration are directly targeting the oligodendrocytes, the key cells affected in Canavan disease.
  • Myrtelle Inc. is a gene therapy company focused on developing transformative treatments for neurodegenerative diseases.
  • The company has a proprietary platform, intellectual property, and portfolio of programs and technologies supporting innovative gene therapy approaches for neurodegenerative diseases.

Myrtelle Announces Positive Preliminary Clinical Data for Its Proprietary Gene Therapy in Canavan Disease

Retrieved on: 
Tuesday, February 15, 2022

In Canavan disease (CD), the production of myelin is affected due to a mutation in the Aspartoacylase gene (ASPA) responsible for coding the enzyme Aspartoacylase (ASPA).

Key Points: 
  • In Canavan disease (CD), the production of myelin is affected due to a mutation in the Aspartoacylase gene (ASPA) responsible for coding the enzyme Aspartoacylase (ASPA).
  • Myrtelle entered into an exclusive worldwide licensing agreement with Pfizer Inc. in 2021 to develop and commercialize this novel gene therapy for the treatment of CD.
  • We are encouraged by the initial findings in the 3 patients treated thus far in this landmark gene therapy trial in Canavan disease.
  • The ongoing clinical trial is expected to continue to generate the critical data needed for further development of this novel gene therapy in the patients with Canavan disease, said Armen Asatryan, MD, MPH, Chief Medical Officer of Myrtelle.

Brett. R. Kockentiet MD, FAAD, is recognized by Continental Who's Who

Retrieved on: 
Tuesday, October 5, 2021

DUBLIN, Ohio, Oct. 5, 2021 /PRNewswire/ -- Brett. R. Kockentiet MD, FAAD, is being recognized by Continental Who's Who as a Lifetime Achiever for his dedicated career in the field of Dermatology and in recognition of his prestigious work at Affiliated Dermatology and Cosmetic Surgery Center Inc.                

Key Points: 
  • Dr. Kockentiet next attended Virginia Commonwealth University Health System, where he completed a 3 year residency in Dermatology in 2009.
  • Dr. Kockentiet wrote several articles during his early career, including "Contact dermatitis in athletes," co-written with Brian B. Adams.
  • Dr. Kockentiet loves helping his patients reduce their discomfort and love the visible results they see on their skin.
  • Dr. Kockentiet previously worked as a Clinical Assistant Professor of Dermatology at the Ohio University Heritage College of Osteopathic Medicine.

Columbus Aesthetic & Plastic Surgery Grows to Six Plastic Surgeons and Dermatologist on Staff

Retrieved on: 
Tuesday, September 7, 2021

COLUMBUS, Ohio, Sept. 7, 2021 /PRNewswire-PRWeb/ -- Columbus Aesthetic & Plastic Surgery (CAPS), central Ohio's largest private plastic surgery practice, is pleased to announce the addition of their sixth plastic surgeon, Jason D. Hehr, M.D., and a medical dermatologist, Jaclyn Wetli, M.D., to their renowned team of doctors.

Key Points: 
  • COLUMBUS, Ohio, Sept. 7, 2021 /PRNewswire-PRWeb/ -- Columbus Aesthetic & Plastic Surgery (CAPS), central Ohio's largest private plastic surgery practice, is pleased to announce the addition of their sixth plastic surgeon, Jason D. Hehr, M.D., and a medical dermatologist, Jaclyn Wetli, M.D., to their renowned team of doctors.
  • CAPS is one of the only plastic surgery practices in the nation to have a full-time dermatologist on staff.
  • Founded in 1997, Columbus Aesthetic & Plastic Surgery is the premier central Ohio plastic surgery practice, with a team of renowned plastic surgeons, certified nurse injectors, and an extensive team of highly skilled medical aestheticians and laser skin and hair restoration specialists.
  • Columbus Aesthetic & Plastic Surgery has offices at 5005 Arlington Centre Blvd in Upper Arlington and at 4030 Easton Station, Suite 260 in Easton Town Center in Columbus.